Identifying Patients With BCG-Unresponsive High-Risk NMIBC Suitable for Treatment With TAR-200
December 14th 2023TAR-200 is being studied for carcinoma in situ with or without papillary disease since it addresses diffuse CIS that cannot be surgically removed, though future trials will expand to papillary disease as adjuvant therapy like BCG, with the goal of extending the disease-free period before potentially reintroducing therapy as needed.
Watch
An Overview of Institution-Led Programs for Bispecific Engager Administration
December 14th 2023Brooke Peters, PharmD, BCOP, provides a comprehensive overview of her institution’s bispecifics administration program, highlighting several agents and the hematologic/oncologic conditions they treat.
Watch
Utilizing Interpretable AI to Distinguish prePMF From ET
December 10th 2023Andrew Srisuwananukorn, MD, discusses the main findings from research of an artificial intelligence-powered machine learning algorithm which evaluated digital whole-slide images of diagnostic bone marrow biopsies and accurately differentiated prefibrotic primary myelofibrosis from essential thrombocythemia.
Watch